Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07413757
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Sponsor: AstraZeneca
View on ClinicalTrials.gov
Summary
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Official title: A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
590
Start Date
2026-03-02
Completion Date
2026-07-31
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Locations (1)
Research Site
Chengdu, China